Leading European Intellectual Property firm announces the promotion of two equity partners, two new partners along with a new IP Director whilst strengthening its legal team in Munich with new Senior Associate
LONDON – Intellectual Property firm Mewburn Ellis today announces four promotions to the partnership, taking effect from 1 April 2023. Adam Gregory and Simon Parry are appointed as full members of the partnership whilst Andrew Williams and Sean Constable become junior members of the partnership.
Adam Gregory is part of the Life Sciences team based in Manchester, where he works with biotech companies to build and manage patent portfolios, draft patent applications and coordinate prosecution worldwide. He leads the firm’s future food team which focusses on alternative protein technologies and is a regular contributor to the wider conversation around protecting innovation in this field. He joined Mewburn Ellis LLP in 2012, qualifying as a Chartered Patent Attorney and a European Patent Attorney in 2016 and joined the partnership in 2020.
Simon Parry is part of the Engineering team based in Manchester. Working for a range of clients including Swedish automotive engineering multinationals, British multinationals, UK innovators, US LLCs and global sports brands, Simon is experienced in patent drafting, prosecution, oppositions and appeals as well as Freedom to Operate opinions. He qualified as a European Patent Attorney in 1999 and a Charted Patent Attorney in 2000, and joined the partnership in 2008.
Andrew Williams has been part of the Chemistry team in Manchester since joining Mewburn in 2020. Andrew has worked in the IP sector since 2006, including over 10 years in-house at a leading global biopharmaceutical firm. Andrew primarily works with large and small pharma companies, which involves extensive patent drafting, prosecution, IP strategy, freedom to operate work and more specialist advice on the overall exclusivity picture for pharma assets as part of due diligence work.
Sean Constable is part of the Life Sciences team based in London. He joined the firm 2014, qualifying as a Chartered Patent Attorney and a European Patent Attorney in 2018. Sean handles mainly life sciences work with experience in a range of sectors including gene editing and antibody therapeutics. He represents clients in a number of multi-party opposition cases before the European Patent Office.
The firm also welcomes Alessia Dalla Libera who strengthens the Legal team as a Senior Associate based in the Munich office. Alessia brings a wealth of experience as an outside legal counsel for medium sized enterprises in the technology and innovation sectors. Alessia previously handled complex licensing and collaboration deals, IP restructuring, acquisitions and disposals, technology transfer advice and due diligence projects.
These appointments are accompanied by the promotion of Scott Armstrong who becomes an IP Director. Scott is a member of the life sciences team, working primarily in the biopharma sector. Scott works with drug discovery/development companies in Europe and the US with a focus on stem cell-enabling technologies, immune-oncology therapies, and diagnostic and prognostic technologies. He also works with Korea-based biopharma companies operating in the therapeutic proteins and industrial fermentation fields.
Richard Johnson, Chairperson at Mewburn Ellis, said:
“Our latest set of partner and director appointments enhances the strength and depth of our team across all of our practice groups and reflects the huge breadth of demand for expertise we see from our clients.
“I am particularly pleased to welcome Alessia in Munich. Adding her experience and skillset to our Legal team will be of enormous value across our client base, and continues the expansion of our offering in Europe.”
| MORE NEWS | | SHARE NEWS WITH OUR EDITOR |
